<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01691209</url>
  </required_header>
  <id_info>
    <org_study_id>16200</org_study_id>
    <secondary_id>2012-001504-38</secondary_id>
    <nct_id>NCT01691209</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis</brief_title>
  <acronym>Phoenix</acronym>
  <official_title>An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study shall explore whether treatment of atopic dermatitis is equally effective with
      Phoenix medical device as compared to standard therapy (Hydrocortisone cream).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Vital signs consist of blood pressure, heart rate and body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Local scored atopic dermatitis (SCORAD) as clinical assessment by means of the intensity items of the SCORAD index</measure>
    <time_frame>Up to 29 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Transepidermal water loss (TEWL) as a measure for skin barrier function</measure>
    <time_frame>Up to 29 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Skin hydration by means of corneometry</measure>
    <time_frame>Up to 29 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Erythema by means of chromametry</measure>
    <time_frame>Up to 29 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of pruritus by means of visual analogue scale (VAS)</measure>
    <time_frame>Up to 29 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Phoenix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application over 29 days twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application over 29 days twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated skin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be observed over 29 days without study treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phoenix (BAY81-2996)</intervention_name>
    <description>Topical formulation applied to the skin</description>
    <arm_group_label>Phoenix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Hydrocortison cream</intervention_name>
    <description>1% Hydrocortison cream applied to the skin</description>
    <arm_group_label>Hydrocortison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Caucasians aged between 18 and 60 years

          -  Patients with mild atopic dermatitis (AD) presenting a scoring AD (SCORAD) rating
             below 50

          -  Skin type I - IV according to Fitzpatrick

          -  Acute AD symptoms on each assessment areas (local SCORAD ≥ 3 and &lt;= 12) at Baseline

          -  Acute symptom of pruritus at Baseline

        Exclusion Criteria:

          -  Any other skin disease at the test area that would interfere with the clinical
             assessment in the opinion of the investigator

          -  Moles, tattoos, strong pigmentation, or scars at the test area that would interfere
             with the clinical assessment

          -  Regular intake of antiphlogistic drugs (for example nonsteroidal anti-inflammatory
             drugs [NSAIDs])

          -  Any condition or treatment which might influence the trial (e.g. any treatment with
             topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as
             well as during the trial (exception: topical treatment of AD lesions other than the
             test areas (for example, face) with low potency steroids restricted to small areas)

          -  UV-therapy or the use of solarium within 30 days before screening as well as during
             the trial

          -  Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy)
             within 30 days before screening as well as during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2012</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <name_title>Head Medical Affairs</name_title>
    <organization>Bayer HealthCare AG, Consumer Care</organization>
  </responsible_party>
  <keyword>Phoenix</keyword>
  <keyword>Hydrocortison</keyword>
  <keyword>mild atopic dermatitis</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

